SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-22-007875
Filing Date
2022-05-05
Accepted
2022-05-05 16:31:44
Documents
13
Period of Report
2022-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyt-20220331.htm   iXBRL 8-K 53850
2 EX-99.1 cyt-ex99_1.htm EX-99.1 178926
  Complete submission text file 0000950170-22-007875.txt   365666

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cyt-20220331_lab.xml EX-101.LAB 13987
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cyt-20220331.xsd EX-101.SCH 2469
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cyt-20220331_pre.xml EX-101.PRE 11454
7 EXTRACTED XBRL INSTANCE DOCUMENT cyt-20220331_htm.xml XML 4895
Mailing Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421
Business Address 128 SPRING STREET BUILDING A, SUITE 510 LEXINGTON MA 02421 857-285-4140
Cyteir Therapeutics, Inc. (Filer) CIK: 0001662244 (see all company filings)

IRS No.: 455429901 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40499 | Film No.: 22896897
SIC: 2834 Pharmaceutical Preparations